Invex Therapeutics Ltd has released a press release.
First US Clinical Site Activated in IIH EVOLVE Phase III
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Story so far
Earlier from Invex Therapeutics
- Invex Receives Approval for Paediatric Plan from the EMA
- MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
- First Patient Randomised in IIH EVOLVE Phase III Trial
- Invex Receives $0.46 Million R&D Tax Rebate
- First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
Later from Invex Therapeutics
- Half Year Accounts
- German Approval for IIH EVOLVE Phase 3 Clinical Trial
- Israel Ministry of Health Approval for IIH EVOLVE
- Invex Receives Regulatory Approval for IIH EVOLVE in France
- Invex Granted European Orphan Drug Designation for TBI
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics